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Abstract 
Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal 
adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell 
attachment, migration, proliferation and survival, all of which are essential for the progression of 
peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK 
activity exhibited a potent anticancer effect in several cancer models, we hypothesized that 
TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent 
the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited 
the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the 
matrix surface was minimally inhibited when FAK activity and expression was suppressed by 
TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the 
cells could attach to the peritoneum and begin to grow within 24 h regardless of the 
pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least 
for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after 
inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral 
administration of TAE226 greatly reduced the size of disseminated tumors and prolonged 
survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal 
dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative 
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and anti-invasion/anti-migration mechanisms. 
Key words: focal adhesion kinase; TAE226; peritoneal dissemination; prolonged survival; 
anti-proliferation; colon cancer 
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1. Introduction  
 
 Peritoneal dissemination is one of the worst progression states of all gastrointestinal 
malignancies. Although improved surgical, chemotherapy and radiotherapy methods have been 
developed, peritoneal dissemination still takes place [1], especially in cases of colorectal cancer. 
In order to overcome this terrible abdominal malignancy, there is an urgent need to clarify the 
molecular mechanism of peritoneal dissemination and to identify agents that specifically prevent 
these mechanisms [2]. 
 Peritoneal dissemination is a complex multistep process, but can be divided into three 
basic stages: the detachment of cancer cells from the primary tumor; attachment to the peritoneal 
surface in the abdominal cavity; growth, migration and invasion within the peritoneum [3]. Many 
adhesion molecules, matrix proteases, motility factors and angiogenic factors are involved in this 
process and so far no specific targeting therapy has been developed. 
 Focal adhesion kinase (FAK) is a 125-kDa non-receptor and non-membrane protein 
tyrosine kinase that is the canonical mediator of integrin signal pathways [4]. Growth factors or 
clustering of integrins facilitate the rapid phosphorylation of FAK at Tyr397 followed by 
subsequent full catalytic FAK activation [4, 5]. Activated FAK mediates several signaling 
pathways which are involved in cell adhesion, growth, proliferation, migration, survival and 
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angiogenesis, all of which are often dysfunctional in tumor cells [6, 7]. 
 Researchers found that FAK mRNA was up-regulated in invasive and metastatic 
human tumor samples [8]. In fact, numerous studies have reported FAK overexpression in 
various tumor cells, including malignant tumors of the pancreas, ovary, cervix, bone, kidney, 
lung, prostate, brain, skin, thyroid, colon, head and neck, as well as in cases of acute myeloid 
leukemia [7]. Additionally, the overexpression of FAK correlates with increased tumor 
malignancy. Intense expression of FAK was detected by immunohistochemistry in colorectal 
tumors and colon cancer cell lines [9]. Therefore, we hypothesized that FAK may play a central 
role in cell attachment, migration, invasion, cell proliferation and angiogenesis during the process 
of peritoneal dissemination.  
 TAE226 is a novel ATP-competitive tyrosine kinase small-molecule inhibitor designed 
to target FAK and can effectively prevent FAK phosphorylation [10]. It has shown potent 
anticancer effects in vitro and in vivo in several types of malignancies [10-15]. 
 Based on this background research, in the present study we examined the anti-tumor 
effect of TAE226 on colon cancer cells, especially focusing on whether TAE226 prevents the 
occurrence and progression of peritoneal dissemination using a mouse model in which HCT116 
colon cancer cells were intraperitoneally inoculated to develop disseminated tumors in the 
peritoneum. 
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2. Materials and Methods  
 
2.1. Cell lines and cultures 
 The colon carcinoma cell line HCT116 was cultured in an RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS; Gemini Biologicals, West Sacramento, CA, 
USA), 100 units/ml of penicillin G sodium, 100 μg/ml of streptomycin (Invitrogen, Carlsbad, 
CA, USA), and maintained in a monolayer culture at 37°C in humidified air with 5% CO2. Three 
other colorectal cancer cell lines (RPMI4788, LoVo and DLD-1) were also used to assess their 
reproducibility in animal experiments. 
 
2.2. Reagents 
TAE226, a tyrosine kinase inhibitor of FAK, was synthesized and provided by 
Novartis Pharma AG (Basel, Switzerland) through a materials transfer agreement with Okayama 
University. Stock solutions of the compound were reconstituted with dimethyl sulfoxide (DMSO; 
Sigma-Aldrich, St. Louis, MO, USA) and diluted with culture media before use. The final 
DMSO concentration in all cultures was 0.025%. For oral administration to mice, TAE226 was 
dissolved in 0.5% methylcellulose as a solvent to make a final concentration of 10 mg/ml.   
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2.3. Cell proliferation assay 
 Cell viability was assessed using the cell proliferation reagent WST-1 (Roche, 
Mannheim, Germany). After treatment with TAE226 for 48 h, WST-1 reagent was added to the 
cells and incubated for 1 to 4 h at 37°C. The absorbance (420-480 nm) of the samples against a 
background control was measured by microplate reader (Thermo Scientific, Rockford, IL, USA). 
Dose effect plots were created to calculate the IC50 of TAE226 using Calcusyn software 
(Biosoft). 
 
2.4. Cell adhesion assay  
 Diluted rat tail collagen-I and human fibronectin (BD Biosciences, Franklin Lakes, NJ, 
USA) were coated to a 96-well plate, followed by blocking with 5% bovine serum albumin 
(BSA) for 1 h and rinsing with phosphate buffered saline (PBS) before use. Pretreated HCT116 
cells with TAE226 (0-10 μM) were suspended in a serum-free RPMI-1640 medium 
supplemented with 0.5% BSA, and a cell suspension with either TAE226 or DMSO was added 
to the pre-coated plate and incubated for 1 h. After non-adherent cells were washed away with 
PBS, WST-1 reagent was added to the plate to evaluate the number of attached cells on the 
matrix. 
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2.5. Cell migration assay 
 A migration assay was performed using a cell culture insertion system (BD Falcon, San 
Jose, California, USA) [16]. Inserts with 8μm pore membranes were placed in a 24-well plate 
containing RPMI-1640 medium, in which 10% FBS stimulated cell migration as a chemotactic 
factor. HCT116 cells (30×10
4
/insert) suspended in a serum-free medium with TAE226 were 
added to the top of the insert. After 12 h, the cells that did not migrate were removed by swabbing, 
and the cells that migrated to the lower surfaces of the inserts were fixed in methanol and stained 
using a Diff-Quick kit. The migrated cells were quantified under the microscope (20 
×magnification) by counting from five individual fields of each membrane.  
 
2.6. FAK small interference RNA transfection 
 The FAK-siRNA (sense strand 5'-GAAUCAGUUACCUAACGGACA-3'; anti-sense 
strand 5'-UCCGUUAGGUAACUGAUUCCU-3') were synthesized by Sigma-Aldrich (St. Louis, 
MO, USA). Scrambled RNA duplexes (5'-GUACCGCACGUCAUUCGUAUC-3' and 
5'-UACGAAUGACGUGCGGUACGU-3') bearing no sequence homology with any known 
human mRNA sequences were used as a control. Double stranded RNAs were transfected into 
cells using Lipofectamine
 
2000 according to the manufacturer’s protocol (Invitrogen, Carlsbad, 
CA, USA). The transfected cells were used for further experiments.  
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2.7. Western blot analysis 
 Cells treated with TAE226 or siRNA were lysed with a protein lysis buffer (M-PER, 
mammalian protein extraction reagent; Thermo Scientific, Rockford, IL, USA), and the protein 
concentration was determined using a BCA
 
Protein Assay Kit (Thermo scientific, Rockford, IL, 
USA). Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis on 
10% acrylamide gels. The separated proteins were then transferred onto PVDF filter membranes 
(GE Healthcare, Buckinghamshire, UK) and incubated with primary antibodies at 4°C overnight, 
followed by incubation with peroxidase-linked secondary antibodies at room temperature for 1 h. 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA) 
was used for signal detection. The antibodies used for western blot analysis were the following: 
anti-human phosphorylated-FAK (Tyr397; BD Biosciences, Franklin Lakes, NJ, USA), 
anti-human total FAK (BD Biosciences); anti-actin (Sigma-Aldrich); Peroxidase-conjugated 
affinipure goat anti-mouse IgG and anti-rabbit IgG (Jackson Immuno Research, West Grove, PA, 
USA). 
 
2.8. Animal experiments 
         BALB/cAJc1-nu/nu 6-week-old male mice derived from C.B-17/Icr (Clea, Tokyo, 
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Japan) were used in this study. The mice were maintained under pathogen-free conditions and the 
mouse experiments were carried out in accordance with the standards and guidelines of the 
Department of Animal Resources at Okayama University and followed "Principles of laboratory 
animal care" (NIH publication No. 85-23, revised 1985). The anesthetized mice were subjected 
to animal models bearing disseminated tumors in the abdominal cavity by injecting 5x10
6
 cells 
for the following experiments: 1) transiently transduced cells with either FAK-siRNA or 
control-siRNA were injected, and the mice were sacrificed 48 h after injection to obtain the 
peritoneum, 2) cells pretreated with TAE226 for 2 h were injected, and the mice were sacrificed 
48 h after injection to obtain the peritoneum, 3) the cells were injected into mice which received 
an oral administration of 100 mg/kg of TAE226 for 2 days before the cell injection and another 
2-day administration thereafter, and then the mice were sacrificed to obtain the peritoneum, 4) 
the cells were injected and from the next day, TAE226 (60 mg/kg) or methylcellulose as a 
vehicle was orally administered once a day and continued for 14 days, and then the mice were 
sacrificed to obtain the peritoneum, 5) the cancer cells were injected and from the next day the 
mice were treated with a 5-day course of TAE226 (60 mg/kg) followed by 2-days off (no 
administration). The treatment continued up to 4 courses and then follow-up was done to track 
their survival periods. 
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2.9. Immunofluorescence Staining 
 Surgically resected tumor tissues from the mice were embedded in Tissue-Tek OCT 
compound (Sakura Finetechnical, Tokyo, Japan) and immediately frozen in liquid nitrogen. 
Fresh frozen sections of 6 µm were dried and fixed with acetone for 10 min. After washing with 
PBS, the sections were blocked with normal goat serum for 10 min followed by incubation with 
a primary antibody for phosphorylated-FAK (Tyr397; Abcam, Cambridge, MA, USA) for 60 
min. After washing, the sections were subsequently reacted with goat anti-mouse IgG antibody 
labeled with FITC (ICN Pharmaceuticals, Costa Mesa, CA, USA) for 1 h. Propidium iodide was 
used for counterstaining. The slides were mounted with Perma-flour (Thermo Scientific) and 
examined under fluorescence microscopy. All procedures were done at room temperature. 
 
2.10. Statistical analysis 
 Student’s t-test was used to compare data between two groups. Data represent the 
mean ± SD. Overall survival was calculated using the Kaplan-Meier method and compared by 
the log-rank test. A P < 0.05 was considered statistically significant. 
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3. Results  
 
3.1. Effects of TAE226 on FAK activity and proliferation of HCT116 colon cancer cells 
 Firstly, among four colorectal cancer cell lines (HCT116, RPMI4788, LoVo, and 
DLD-1), we found that HCT116 cells had the highest expression and activation of FAK (data 
not shown). When HCT116 cells were treated with TAE226 for 1 h, the inhibition of FAK 
phosphorylation at Tyr397 was noted at 1 μM and maximal inhibition was reached at 5 μM (Fig. 
1A), without affecting the expression of FAK (Fig. 1A). 
 Next, a 48 h exposure to different concentrations of TAE226 induced a dose-dependent 
inhibition of cell proliferation in HCT116 cells (Fig. 1B). The 48 h treatment with TAE226 
resulted in a 48.6% growth inhibition at a concentration of 0.1 μM and a 80.3% inhibition at 1 
μM. The IC50 of TAE226 in HCT116 cells was 0.2185 μM（r=0.9890). 
 
3.2. Effects of TAE226 on cell attachment and migration in vitro 
 FAK is intimately involved in the coordination of adhesion formation and turnover 
which regulates cell movement [17]. The migration of HCT116 cells was significantly inhibited 
by TAE226 in a dose-dependent manner (Fig. 1C), while the attachment of cells to the matrix was 
only minimally suppressed (Fig. 1D). Even the pretreatment of HCT116 cells with different 
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concentrations of TAE226 did not improve the inhibitory effect on cell attachment (data not 
shown). Although treatment with 5 μM of TAE226 significantly decreased the number of cells 
migrating through Boyden chambers with a 56.85%-reduction rate (Fig. 1C), TAE226 showed a 
minimal inhibitory effect on the attachment of HCT116 cells.  
 
3.3. Silencing of FAK by siRNA had no effect on cell attachment in vitro and in vivo 
 Our data showed that the inhibition of FAK activity by TAE226 had a minimal effect 
on the attachment of HCT116 cells. Therefore, we wanted to explore whether the suppression of 
FAK expression by FAK-siRNA affected the HCT116 cell attachment. Western blot analysis 
showed that transfection with FAK-siRNA induced a significant decrease of FAK expression (Fig. 
2A). However, the cell adhesion assay result indicated that the knockdown of FAK expression did 
not affect cell attachment to the matrix (Fig. 2B). Furthermore, when siRNA-transduced 
HCT116 cells were inoculated into the abdomen of mice, the silencing of FAK expression did 
not affect cancer cell attachment on the peritoneum and even began to grow equally to the 
control (Fig. 2C and D), indicating that the activity and expression of FAK is not so essential for 
physical cell attachment.  
 
3.4. Effects of TAE226 on cell attachment in vivo 
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Since TAE226 demonstrated its potent inhibitory effects on cell proliferation and 
migration, our next question was whether the progression of peritoneal dissemination could be 
suppressed by TAE226. We first pretreated HCT116 cells with 10μM of TAE226 for 2 h, 
enough to suppress FAK activity, and subsequently inoculated those pretreated cells into 
abdomen of mice. Similar to the experiment using siRNA, the in vitro pretreatment of HCT116 
cells with TAE226 did not show any apparent difference compared to the control treatment 
(DMSO) (Fig. 3A and B). On the other hand, when TAE226 was orally administered to the mice 
from 2 days before the inoculation and thereafter, the number of peritoneum-attached cells was 
significantly reduced (68%-reduction from control, p=0.004668; Fig. 3C and D). Since we 
could observe a similar reduction of developing peritoneal dissemination using other colorectal 
cancer cell lines (RPMI4788, LoVo and DLD-1, Supplementary Fig. S1), these reproducible 
data tempted us to consider that systemically saturating TAE226 in a mouse body through oral 
administration can increase the negative regulation of the progression of peritoneal 
dissemination. 
 
3.5. In vivo effect of TAE226 on the development of peritoneal disseminated tumors 
 As we described above and [14, 15], TAE226 inhibited cancer growth and migration in 
vitro and in vivo, whereas it cannot fully suppress cell attachment or the occurrence of 
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peritoneal dissemination. Hence, we hypothesized that the best practice of TAE226 treatment is 
to reduce the progression of peritoneal dissemination, leading to prolonged survival, since 
disseminated tumor-bearing patients often have short survivals regardless of receiving 
multidisciplinary treatment. In order to prove this hypothesis, we extended the treatment periods 
with TAE226 and monitored the survival of treated mice with disseminated tumors. 
Fourteen-day treatment with TAE226 apparently reduced the size of disseminated tumors (Fig 
4A and B) accompanied by a reduction of FAK activity (Fig. 4C), and the tumor area was 
significantly diminished (control vs TAE226 = 100.0 ± 20.80 vs 20.4 ± 9.80, p=0.000678; Fig 
4D). Further extension of TAE226 treatment significantly prolonged the living periods of 
disseminated tumor-bearing mice (median survival time; control: 26.5 days, TAE226: 36.5 days, 
p=0.00082; Fig. 4E), indicating that targeting FAK by the oral administration of TAE226 can be 
a potential application for negatively controlling peritoneal carcinomatosis.   
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4. Discussion 
      
       FAK has been linked to cell adhesion, migration, proliferation, survival and 
angiogenesis, all of which are crucial for the progression of peritoneal dissemination. In this 
study, we found that TAE226 can significantly inhibit cell proliferation and migration, while the 
effect on inhibiting cell attachment appeared to be modest. Since several papers reported that 
focal adhesions can still form in FAK-deficient cells [18,19], it was reasonable to believe that the 
treatment with TAE226 or siRNA still allowed HCT116 cells to achieve initial cell attachment 
on the matrix. Hence, at the nascent focal adhesions, clustered integrins recruit FAK and FAK 
subsequently facilitates the maturation of focal adhesions [19]. Based upon this fact, the intrinsic 
value of the suppression the FAK activity by TAE226 is the inhibition of cell migration and 
subsequent proliferation, as we demonstrated above.  
 It is noteworthy that pretreatment of cancer cells by TAE226 did not affect their 
attachment to the peritoneum (Fig. 3A, B). However, the treatment of mice before and after 
inoculation reduced cell attachment to the peritoneum (Fig. 3C, D). This seems to be a 
contradiction. Of course it is possible that the TAE226 pretreated cells might recover their FAK 
activity during cell transplant to the peritoneum, however, as we mentioned above, we assume 
that FAK may not be essential for initial cell attachment, considering the result of the siRNA 
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experiments (Fig. 2). In addition, the pretreatment of mice with TAE226 might have provided a 
change of microenvironment which was unsuitable for cancer cells to attach, migrate and 
proliferate. Some papers described that the tumor microenvironment is a major part of the most 
important circumstances in cancer progression [20, 21]. Indeed, FAK is overexpressed not only 
in tumor tissues but in tumor-associated stromal cells, thus systemically saturating a mouse body 
with TAE226 could be a dual inhibition of FAK signaling in both cancer cells and tumor 
environment, which may be a unique and reasonable approach as a novel cancer treatment.  
 Controlling peritoneal dissemination is very difficult with existing therapeutic 
modalities, resulting in a poor outcome in general. One of the reasons is that generally 
disseminated tumors spread widely in the abdomen, which makes it difficult to target cancer 
cells without damaging normal abdominal tissues. On the other hand, stromal tissues adjacent to 
disseminated tumors are also involved in the progression of dissemination with the activation of 
some key molecules, including FAK. Thus, a systemic suppression of FAK activity by 
saturation with TAE226 enables a bidirectional negative regulation of dissemination as well as 
invasion and metastasis, possibly leading to better outcomes for tumor-bearing patients.  
 In conclusion, systemic saturation with TAE226 potently reduced the progression of 
peritoneal dissemination with prolonged survival, thus targeting FAK could be a potential 
alternative for advanced cancer treatment. 
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Figure legends 
 
Fig.1. Effects of TAE226 on FAK activity, proliferation, migration and adhesion of colon 
cancer cells. A, The activation of FAK was suppressed by TAE226 treatment in 1 h in a  
dose-dependent manner. B, TAE226 treated HCT116 cells for 48 h with different concentrations. 
The cell viability of HCT116 cells treated with different concentrations of TAE226 was 
measured by WST-1 cell proliferation assay. C, A migration assay was performed using a cell 
culture insertion system. The migrated cells were stained and quantified. D, A cell adhesion 
assay was performed using a 96-well plate coated with type I collagen and fibronectin. After 
washing the non-adherent cells, attached cells were evaluated by measuring the absorbance of 
WST-1. Each column is given as a percentage of live, migrated or attached cells compared with 
the control (treatment with DMSO alone), which was set as 100%. Error bars represent the 
mean ± SD. *p < 0.05 vs. control. 
 
Fig.2. Silencing of FAK expression by siRNA reveals the minimal inhibitory effect on cell 
attachment in vitro and in vivo. A, HCT116 cells were transfected with FAK-siRNA and 
control siRNA for 48 h and the cell lysates were prepared for western blot analysis. B, The ability 
of in vitro cell adhesion on collagen-I was compared between FAK-siRNA transduced HCT116 
cells and control cells with scrambled siRNA. C, HCT116 cells transfected with siRNA were 
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inoculated in the abdomen and the peritoneal tissues were collected 48h after inoculation for the 
detection of peritoneal dissemination. Arrows in the H-E staining pictures indicate the cancer 
cells attached to the peritoneum. Scale bar: 200 μm. D, Peritoneum-attached cells were 
quantified in 10 randomly selected high power fields (40x) to draw histograms. Each column is 
given as a percentage of attached cells compared with the control, which was set as 100%. Error 
bars represent the mean ± SD. 
 
Fig.3. Systemic saturation of host animals with TAE226 exerts its anti-dissemination effect. 
A and B, HCT116 cells were pretreated with either 10μM of TAE226 or DMSO for 2 h before 
intraperitoneal inoculation. Peritoneum tissues were collected 48 h after inoculation, in order to 
detect the disseminated cancer cells by H-E staining (A) and to compare the number of 
peritoneum-attached cells between TAE226-pretreatment and control (DMSO-pretreatment) (B). 
C and D, mice were treated with 100 mg/kg of TAE226 before and after the intraperitoneal 
inoculation of untreated HCT116 cells and peritoneum tissues were collected 48 h after 
inoculation. The disseminated cancer cells were detected by H-E staining (C) and were 
quantified to compare the ability of HCT116 cells to attach on the peritoneum between TAE226 
administration and control (methylcellulose administration) (D). Arrows in pictures A and C 
indicate the peritoneum-attached cancer cells. Scale bar: 200 μm. Each column in B and D is 
given as a percentage of attached cells (control was set as 100%), by which the numbers of 
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attached cells were counted in 10 randomly selected high power fields (40x) per slide. Error bars 
represent the mean ± SD. *p < 0.005 vs. control. 
 
Fig.4. Oral administration of TAE226 contributes to reducing peritoneal dissemination 
and the prolonged survival of tumor-bearing mice. Nude mice were orally administrated with 
TAE226 (60 mg/kg) or methylcellulose after intraperitoneal inoculation with HCT116 cells. A, 
Macroscopic view of the peritoneal cavities at the time of sacrifice was take after a 14-day 
administration of TAE226. Arrows indicate disseminated tumors. B, Collected peritoneum 
tissues were subjected to H-E staining. Scale bar: 500 μm. C, The expression of phosphorylated 
FAK (green) was detected in the tissues taken from the mice treated with either methylcellulose 
(left panel) or TAE226 (right panel). Propidium iodide staining (red) was given as a counterstain 
for the nuclei. Scale bar: 200 μm. D, The area of disseminated tumor in 5 randomly selected 
fields of H-E stained section from each mouse was measured using computer software (Image J). 
The variance of tumor area between the control and TAE226 treated group was statistically 
analyzed by drawing histogram. Each column is given as a percentage of tumor area comparing 
with the control, which was set as 100%. Error bars represent the mean ± SD. *p=0.000678. E, 
Survival periods were tracked to examine the advantage of TAE226 treatment and a survival 
curve was drawn by the Kaplan-Meier method. 
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Supplementary Fig. S1. Oral administration of TAE226 represents a similar inhibitory 
effect on the development of peritoneal dissemination using other colorectal cancer cells. 
Mice were treated with 100 mg/kg of TAE226 before and after intraperitoneal inoculation of 
untreated RPMI4788, LoVo and DLD-1 cells and peritoneum tissues were collected 48 h after 
inoculation. The disseminated cells were detected by H-E staining (A) and were quantified to 
compare the ability for cancer cells to attach on the peritoneum between TAE226 administration 
and methylcellulose only as a control (B-D). Arrows in the H-E staining pictures indicate 
peritoneum-attached cancer cells. Scale bar: 200 μm. Each column in B, C and D is given as a 
percentage of attached cells (control was set as 100%), by which the numbers of attached cells 
were counted in 10 randomly selected high power fields (40x) per slide. Error bars represent  
the mean ± SD. The reduction of peritoneum-attached cells from control was 68% (RPMI, 
*p=0.004064, B), 41% (LoVo, **p=0.011297, C) and 51% (DLD-1, *+p=0.020808, D). 
 
 
 





